Seth Elliott serves as Executive at Immune Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Seth Elliott has executed 1 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Jan 13, 2015 involved receiving (via award) 1,250,000 shares valued at $0.
| DATE | TICKER | VALUE | TYPE | SHARES | PRICE | 10b5-1 |
|---|---|---|---|---|---|---|
| Jan 13, 2015 | IMUN | $0 | Award | 1,250,000 | $N/A | Discretionary |
Seth Elliott currently holds 1,250,000 shares of Immune Therapeutics, Inc. (IMUN), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Seth Elliott has been a net neutral trader of IMUN stock. They have purchased $0 and sold $0 worth of shares.
Seth Elliott's most recent insider trade was on Jan 13, 2015, when they sold 1,250,000 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted